Loading
Nanoparticle-based Drug Delivery · Journal article
Results in Chemistry · August 22, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic narrative review reframing metal-organic frameworks (MOFs) as nanocarriers within a biopharmaceutical framework, integrating nano-bio interactions, ADME/safety considerations, and emerging applications in cancer, gene editing, antibacterial, and regenerative therapies. The review identifies critical translational gaps—insufficient long-term toxicity data, lack of standardized in vitro-in vivo correlation, and limited quantitative pharmacokinetic data—rather than reporting efficacy or safety outcomes.
Narrative review article.
MOF nanocarriers exhibit tunable properties for drug delivery, biologics, catalysis, and multimodal therapy applications Particle size, surface chemistry, protein corona formation, and framework stability influence uptake, endosomal trafficking, and biodistribution Applications examined span cancer chemo-phototherapy, CRISPR gene editing, antibacterial therapy, bone regeneration, and infected wound healing
No original efficacy or safety data reported; review is conceptual and mechanistic No quantitative pharmacokinetic parameters, toxicity thresholds, or clinical trial results provided
The source did not state who this applies to in practice.
This is a mechanistic review synthesizing preclinical and exploratory data on MOF nanocarriers without reporting original clinical trials, hard endpoints, or comparative efficacy results.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metal Organic Frameworks (MOFs) offer tunable nano-platforms for drug delivery, biologics, catalysis and multimodal therapy. However, the clinical implementation of MOFs is limited by an incomplete understanding of nano-bio interactions as well as pharmacological behaviour. This review aims to reframe a mechanistic biopharmaceutical perspective to MOF nanocarriers, integrating dynamics of nano-bio interactions, transport across biological barriers, degradation mechanisms, and immune interactions within the context of absorption, distribution, metabolism, excretion and safety (ADME/safety). Using benchmark systems such as MIL-100, ZIF-8, UiO-66, nanoPCN-890, and Fe-TBP, the influence of particle size, surface chemistry, protein corona formation and framework stability on the uptake, endosomal trafficking and biodistribution of MOFs has been examined. Furthermore, this review compares applications of MOFs in cancer chemo phototherapy, CRISPR gene editing, antibacterial therapy, bone regeneration, and healing of infected wounds. Simultaneously, it focuses on the mechanism of action, in vivo outcomes, and remaining gaps in translation for each of these applications. Some important challenges that need to be addressed to translate MOF-based nanomedicine to clinical settings include insufficient long-term toxicity data, a lack of standardized in vitro-in vivo correlation (IVIVC) of frameworks, and limited availability of quantitative data for pharmacokinetics. This review proposes a mechanistic roadmap linking MOF material design to biological performance, ultimately enabling safer, predictable, and clinically translatable MOF-based nanomedicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.